Insights On Drug Discovery
-
Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge Rodent Models
6/10/2025
Here, we present multiple case studies utilizing clinically relevant mouse and rat models to evaluate key characteristics of potential RSV therapeutics.
-
Preclinical Evaluation Of New Antifibrotics In NASH-Induced Fibrosis Models
6/10/2025
Accelerate the development of antifibrotic therapies through our clinically relevant models, deep scientific expertise, and proven preclinical capabilities in this area of unmet medical need.
-
Preclinical Evaluation Of Antifibrotics In COVID-Induced Fibrosis Model
6/10/2025
Advancing the development of effective antifibrotic therapies requires urgent investment in clinically relevant, IND-enabling preclinical models to address the growing burden of fibrotic diseases.
-
Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge SCID Mouse Models
6/10/2025
Advance your RSV therapeutic pipeline with trusted, IND-enabling preclinical services that deliver clinically relevant data through optimized study designs and validated rodent models.
-
Preclinical Evaluation Of RSV Vaccines And Antivirals In BALB/c Mice
6/10/2025
Accelerate your RSV therapeutic development with clinically relevant preclinical models and expert IND-enabling services that deliver the data needed to advance confidently toward clinical trials.
-
You Need 'Brutal Honesty' When Outsourcing
5/29/2025
Our Outsourced Pharma Live speakers were adamant: You need a clear and honest assessment of what both the sponsor and CDMO need and bring to the relationship.
-
A Brief Intro To CMC Compliance Through CDMO Collaborations
5/29/2025
Chief Editor Louis Garguilo provides a brief introduction and background to our Outsourced Pharma Live Event: CMC Compliance Through CDMO Collaborations.
-
The 3 Models Of Outsourcing
5/29/2025
Jumai Abioye, Ph.D., Founder and CEO, Pan Access Innovations, offers her three models of outsourcing and working with CDMOs, for biotechs of all shapes and sizes.
-
Broad Biodistribution And Expression Of Allele-Selective LETI-101
5/28/2025
Discover how LETI-101, a novel precision-based CRISPR treatment, can leverage targeted delivery and broad brain distribution to transform Huntington's disease treatment.
-
CRISPR Portfolio, Modalities Accelerate Candidate Identification
5/28/2025
See how this cutting-edge, AI-driven genome editing technology can accelerate the development of precise, clinically viable therapies for genetic diseases.